Skip to main content
main-content

13.09.2016 | Original Article | Ausgabe 11/2016

Tumor Biology 11/2016

Determination of a CD4+CD25FoxP3+ T cells subset in tumor-draining lymph nodes of colorectal cancer secreting IL-2 and IFN-γ

Zeitschrift:
Tumor Biology > Ausgabe 11/2016
Autoren:
Morteza Jafarinia, Fereshteh Mehdipour, Seyed Vahid Hosseini, Leila Ghahramani, Masood Hosseinzadeh, Abbas Ghaderi
Wichtige Hinweise
Morteza Jafarinia and Fereshteh Mehdipour have equal contributions to the study.

Abstract

CD4+CD25FoxP3+ cells are a newly recognized subset of T cells which was first reported in autoimmune diseases. In our previous study, this subset was detected in tumor-draining lymph nodes (TDLNs) of patients with breast cancer. As little is known about their function in TDLNs of cancer patients, in this study, their frequency as well as their ability to produce interleukin (IL)-2, IL-10, or interferon (IFN)-γ were investigated in TDLNs of colorectal cancer (CRC) patients. Mononuclear cells were isolated from lymph nodes of 13 patients with CRC using Ficoll-Hypaque gradient centrifugation. Cells were stimulated in vitro and stained with CD25, CD4, FoxP3, IFN-γ, IL-10, and IL-2 or isotype matched antibodies and subjected to flow cytometry. The frequency of CD4+CD25FoxP3+CD127dim/− cells was significantly lower than CD4+CD25+FoxP3+CD127dim/− population in TDLNs of CRC patients. The percentage of CD127dim/− cells and also the MFI of FoxP3 expression was significantly lower in CD4+CD25FoxP3+ in comparison with CD4+CD25+FoxP3+ population. Moreover, CD4+CD25FoxP3+ cells contained higher percentages of IL-2- and IFN-γ-producing cells than CD4+CD25+FoxP3+ subpopulation. But, no difference was seen between two subsets in terms of IL-10 production. CD4+CD25FoxP3+ cells in TDLNs of CRC patients had lower suppressive and higher effector properties in comparison with CD4+CD25+FoxP3+ conventional regulatory T cells.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 11/2016

Tumor Biology 11/2016 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise